Literature DB >> 17605696

Trends in medication use for asthma in school-entry children in the Australian Capital Territory, 2000-2005.

Christine B Phillips1, Helen Toyne, Karen Ciszek, Robyn G Attewell, Marjan Kljakovic.   

Abstract

OBJECTIVE: To analyse trends in asthma medications used by school-entry children whose parents report they have asthma. DESIGN AND
SETTING: Annual cross-sectional study of all school-entry children (about 4400 each year) in the Australian Capital Territory in 2000-2005, by means of a questionnaire for parents on child health status and medication use; and a cross-sectional study of asthma prescriptions for children aged 5 years obtained from the Medicare Australia database for 2002-2005. PARTICIPANTS: All school-entry children in the ACT with parent-reported asthma (numbers in the years 2000-2005 ranged between 435 and 589). MAIN OUTCOME MEASURES: Changes in the use of different medications; changes in delivery devices for asthma; changes in the potency of inhaled fluticasone.
RESULTS: Response rates to kindergarten health screening were in the range 85%-89% for 2000-2005. Parent-reported asthma prevalence ranged from 11% to 15%. Each year, around 35% of children with asthma (age range, 4-6 years) used inhaled corticosteroids. An increase in the use of fluticasone (from 11% to 33% of children with asthma) was offset by decreases in beclomethasone use (from 14% to 3%) and budesonide (from 14% to 4%). Use of cromoglycate and nedocromil fell from 46% to 16%. Nebuliser use decreased (from 45% to 20%), while the use of spacer devices increased (from 70% to 83%). Use of combined salmeterol/fluticasone increased from 8% (in 2002) to 20% (in 2005) of children with parent-reported asthma. These trends were mirrored in Medicare Australia data for 5-year-old children in the ACT.
CONCLUSIONS: There was marked volatility in the types of asthma medication used over the 6 years. Reciprocal trends leading to increased use of spacers and decreased use of nebulisers are in accord with national guidelines for better asthma management. The increasing use of products containing a combination of salmeterol and fluticasone requires ongoing monitoring.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17605696     DOI: 10.5694/j.1326-5377.2007.tb01107.x

Source DB:  PubMed          Journal:  Med J Aust        ISSN: 0025-729X            Impact factor:   7.738


  2 in total

1.  Cost considerations of therapeutic options for children with asthma.

Authors:  Sandra Chuang; Adam Jaffe
Journal:  Paediatr Drugs       Date:  2012-08-01       Impact factor: 3.022

2.  Dispensing Practices of Fixed Dose Combination Controller Therapy for Asthma in Australian Children and Adolescents.

Authors:  Nusrat Homaira; Benjamin Daniels; Sallie Pearson; Adam Jaffe
Journal:  Int J Environ Res Public Health       Date:  2020-08-05       Impact factor: 3.390

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.